Free Trial

Tilray Brands (TSE:TLRY) Shares Up 1.5% - Should You Buy?

Tilray Brands logo with Medical background

Tilray Brands, Inc. (TSE:TLRY - Get Free Report)'s share price traded up 1.5% during mid-day trading on Friday . The stock traded as high as C$0.70 and last traded at C$0.69. 1,955,848 shares changed hands during trading, an increase of 28% from the average session volume of 1,527,762 shares. The stock had previously closed at C$0.68.

Tilray Brands Stock Up 3.1 %

The firm has a fifty day simple moving average of C$0.87 and a 200-day simple moving average of C$1.51. The firm has a market cap of C$431.73 million, a price-to-earnings ratio of -1.62 and a beta of 2.19. The company has a debt-to-equity ratio of 10.76, a quick ratio of 2.16 and a current ratio of 2.54.

Tilray Brands Company Profile

(Get Free Report)

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products through Manitoba Harvest and beer through SweetWater.

Recommended Stories

Should You Invest $1,000 in Tilray Brands Right Now?

Before you consider Tilray Brands, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray Brands wasn't on the list.

While Tilray Brands currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Big Moves: Profit-Taking, Price Targets & AI Potential
Buy Early: 3 Tech Trends With Millionaire-Making Potential
SMCI Stumbles on Earnings: Why Some Investors Still Want In

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines